Spastic paraplegia type 4: A novel SPAST splice site donor mutation and expansion of the phenotype variability

J Neurol Sci. 2017 Sep 15:380:92-97. doi: 10.1016/j.jns.2017.07.011. Epub 2017 Jul 9.

Abstract

Mutations in SPG4/SPAST are the most frequent molecular aetiology in the autosomal dominant form of hereditary spastic paraplegia (HSP). Loss-of-function and haploinsufficiency in SPAST have been demonstrated and the pure form of spastic paraplegia is a main clinical manifestation. This study is to explore the novel SPAST splice site donor variant, c.1004+3A>C, in seven patients from two families, one from Italy and the other from Japan. Exon 6 is skipped out by the variant, leading to a premature termination of translation, p.Gly290Trpfs*5. Measurement of SPAST transcripts in lymphocytes demonstrated a reduction through nonsense-mediated mRNA decay (NMD). Intra- and inter-familial phenotypic variations were observed, including age-at-onset, severity of spasticity, and scoliosis. Our study demonstrated further evidence of allelic heterogeneity in SPG4, dosage effects through NMD, and broad clinical features of the SPAST mutation.

Keywords: Nonsense-Mediated mRNA Decay (NMD); Phenotype variability; SPAST; Spastic paraplegia type 4 (SPG4); Splice site donor variant.

Publication types

  • Case Reports
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Cells, Cultured
  • Cohort Studies
  • Family
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Paraplegia / genetics*
  • Paraplegia / physiopathology*
  • Phenotype
  • RNA Splice Sites / genetics*
  • Spastic Paraplegia, Hereditary / genetics*
  • Spastic Paraplegia, Hereditary / physiopathology*
  • Spastin / genetics*
  • Spastin / metabolism
  • T-Lymphocytes / metabolism

Substances

  • RNA Splice Sites
  • Spastin
  • SPAST protein, human

Supplementary concepts

  • Spastic Paraplegia Type 4